NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Stock Rated “Moderate Buy” by Wall Street Analysts

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have been given an average recommendation of “Moderate Buy” by the six analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $170.00.

A number of equities research analysts have recently weighed in on the company. Weiss Ratings lowered NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. HC Wainwright assumed coverage on NeuroSense Therapeutics in a report on Thursday, September 3rd. They set a “buy” rating for the company.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Yorkville Advisors Global LP acquired a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $77,000. NeuroSense Therapeutics makes up 0.0% of Yorkville Advisors Global LP’s investment portfolio, making the stock its 24th biggest position. Yorkville Advisors Global LP owned about 0.73% of NeuroSense Therapeutics at the end of the most recent quarter. 1.04% of the stock is owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Price Performance

Shares of NASDAQ:NRSN opened at $6.95 on Friday. NeuroSense Therapeutics has a 1 year low of $5.00 and a 1 year high of $26.64. The company has a market cap of $13.21 million, a PE ratio of -0.64 and a beta of 1.60. The stock’s 50-day moving average is $8.93 and its 200 day moving average is $13.15.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is headquartered in Israel and conducts research aimed at addressing biological mechanisms associated with diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurological disorders.

NeuroSense’s leading investigational product is PrimeC, an oral, fixed-dose combination of ciprofloxacin and celecoxib. The therapy is designed to target multiple disease-related pathways, including neuroinflammation and the regulation of RNA processing, and has been evaluated in clinical studies involving patients with ALS.